{
  "nctrialId": "HC-1531",
  "title": "A Randomized Open-Label, Placebo-Controlled  Study of HEM-779 (factor VIII gene therapy) in Patients With Atopic Dermatitis",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled  Study of HEM-779 (factor VIII gene therapy) in Patients With Atopic Dermatitis",
  "sponsor": "Princess Margaret Cancer Centre",
  "indication": "Atopic Dermatitis",
  "phase": "Phase 4",
  "fileName": "HC-1531.json",
  "fileSize": 355259,
  "date": "2024-07-09",
  "completionDate": "2028-02-18",
  "drugName": "HEM-779 (factor VIII gene therapy)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Not yet recruiting",
  "description": "This is a randomized open-label, placebo-controlled  study designed to evaluate the efficacy and safety of HEM-779 (factor VIII gene therapy) in patients with Atopic Dermatitis. The study will enroll approximately 273 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 22-67 years\n- Confirmed diagnosis of Atopic Dermatitis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1531"
}